Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high ROS levels
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Uncontrolled accumulation of reactive oxygen species (ROS) causes oxidative stress and induces harmful effects. Both high ROS levels and p53 mutations are frequent in human cancer. Mutant p53 forms are known to actively promote malignant growth. However, no mechanistic details are known about the contribution of mutant p53 to excessive ROS in cancer cells. Herein we examined the effect of p53R273H, a commonly occurring mutated p53 form, on the expression of phase 2 ROS detoxifying enzymes, and on the ability of cells to readopt a reducing environment after exposure to oxidative stress. Our data suggest that p53R273H mutant interferes with the normal response of human cells to oxidative stress. We show here that upon oxidative stress mutant p53R273H attenuates the activation and function of NF-E2-related factor 2 (NRF2), a transcription factor that induces antioxidant response. This effect of mutant p53 is manifested by decreased expression of phase 2 detoxifying enzymes NQO1 and HO-1 and high ROS levels. These findings were observed in several human cancer cell lines highlighting the general nature of this phenomenon. The failure of p53R273H mutant-expressing cells to restore a reducing oxidative environment was accompanied by increased survival, a known consequence of mutant p53 expression. These activities are attributable to mutant p53R273H gain of function and may underlie its well-documented oncogenic nature in human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 3×
“Under normal conditions this transcription factor is maintained at low levels through constitutive proteosomal degradation mediated by the E3 ubiquitin ligase (Kobayashi et al., 2004; Kobayashi and Yamamoto, 2005).”
BackgroundMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 2×
“It was shown that mice expressing either mutant p53R270H (human p53R273H) or p53R172H (human p53R175H) developed broader spectrum of tumors that exhibited higher level of metastasis compared with either p532/2 or p532/+ mice (Lang et al., 2004; Olive et al., 2004).”
BackgroundWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 3×
“…as mutant p53 ‘‘gain of function’’ may lead to enhanced cell proliferation, invasiveness, metastasis and resistance to a variety of anti-cancer drugs (Brosh and Rotter, 2009; Buganim et al., 2010; Kogan-Sakin et al., 2011; Muller et al., 2009; Stambolsky et al., 2010; Stambolsky et al., 2010).”
BackgroundSelf-citationRamos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 2×
“It was shown that mice expressing either mutant p53R270H (human p53R273H) or p53R172H (human p53R175H) developed broader spectrum of tumors that exhibited higher level of metastasis compared with either p532/2 or p532/+ mice (Lang et al., 2004; Olive et al., 2004).”
BackgroundVousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 3×
“Numerous studies have indicated increased ROS activity in cancer cells when compared with normal cells (Valko et al., 2001; Valko et al., 2006; Vousden and Ryan, 2009).”
BackgroundModulation of the Vitamin D3 Response by Cancer-Associated Mutant p53
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245 · cited 3×
“…as mutant p53 ‘‘gain of function’’ may lead to enhanced cell proliferation, invasiveness, metastasis and resistance to a variety of anti-cancer drugs (Brosh and Rotter, 2009; Buganim et al., 2010; Kogan-Sakin et al., 2011; Muller et al., 2009; Stambolsky et al., 2010; Stambolsky et al., 2010).”
BackgroundSelf-citationValko, M., Morris, H., Mazúr, M., Rapta, P., & Bilton, R. F. (2001) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(01)00163-5 · Cited by 124 · cited 5×
“On the other hand, uncontrolled accumulation of ROS leads to ‘‘oxidative stress’’ which represents the harmful effects of ROS including damage to cell structure, nucleic acids, lipids and proteins (Cho et al., 2006; Valko et al., 2001; Valko et al., 2006).”
BackgroundInfluentialBuganim, Y., Solomon, H., Rais, Y., Kistner, D., Nachmany, I., Brait, M., Madar, S., Goldstein, I., Kalo, E., Adam, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2661 · Cited by 77
Self-citation
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
“Furthermore, mutant p53 can also promote the function of proteins including SREBP, NF-Y, VDR, ETS2, or NRF2, resulting in increased proliferation, cholesterol synthesis, accumulation of reactive oxygen species, and enhanced cell survival (Do et al., 2012; Freed-Pastor et al., 2012; Kalo et al., 2012; Liu et al., 2011;…”
BackgroundInfluentialThe Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway
Baird, L., & Yamamoto, M. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00099-20 · Cited by 1,542
Hallmarks of glycosylation in cancer
Munkley, J., & Elliott, D. J. (2016) · Oncotarget · doi:10.18632/oncotarget.8155 · Cited by 521
Katerji, M., Filippova, M., & Duerksen-Hughes, P. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/1279250 · Cited by 429
Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321
Metadata
- Authors
- Kalo, E., Kogan-Sakin, I., Solomon, H., Bar-Nathan, E., Shay, M., Shetzer, Y., Dekel, E., Goldfinger, N., Buganim, Y., Stambolsky, P., Goldstein, I., Madar, S., & Rotter, V.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2012-01-01
- Volume
- 125
- Issue
- Pt 22
- Pages
- 5578-86
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2124446528
- Cited by
- 103
- References
- 10
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.